Healthcare provider profile · identity verified

Carlos E Alvarez-Meraz, MD

Internal Medicine · SAN ANTONIO, TX · NPI 1356450050

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	183	52
Atorvastatin Calcium	Atorvastatin Calcium	157	47
Rosuvastatin Calcium	Rosuvastatin Calcium	109	35
Gabapentin	Gabapentin	99	31
Metformin Hcl	Metformin Hcl	96	29
Metoprolol Succinate	Metoprolol Succinate	85	24
Amlodipine Besylate	Amlodipine Besylate	83	24
Allopurinol	Allopurinol	74	20
Trazodone Hcl	Trazodone Hcl	64	23
Ozempic	Semaglutide	63	12
Montelukast Sodium	Montelukast Sodium	61	17
Omeprazole	Omeprazole	59	20
Lisinopril	Lisinopril	57	16
Simvastatin	Simvastatin	54	14
Jardiance	Empagliflozin	52	suppressed
Losartan Potassium	Losartan Potassium	50	17
Ezetimibe	Ezetimibe	48	18
Venlafaxine Hcl Er	Venlafaxine Hcl	46	13
Zolpidem Tartrate	Zolpidem Tartrate	46	11
Clonazepam	Clonazepam	37	suppressed
Sertraline Hcl	Sertraline Hcl	36	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	35	12
Synthroid	Levothyroxine Sodium	35	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	35	12
Tramadol Hcl	Tramadol Hcl	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	34	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	33	suppressed
Famotidine	Famotidine	32	12
Memantine Hcl Er	Memantine Hcl	32	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	32	suppressed
Mirtazapine	Mirtazapine	31	12
Eliquis	Apixaban	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	11
Baclofen	Baclofen	29	11
Escitalopram Oxalate	Escitalopram Oxalate	29	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Pregabalin	Pregabalin	28	15
Mounjaro	Tirzepatide	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Raloxifene Hcl	Raloxifene Hcl	25	suppressed
Furosemide	Furosemide	23	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	23	12
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Finasteride	Finasteride	21	suppressed
Lubiprostone	Lubiprostone	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Alprazolam	Alprazolam	19	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Potassium Chloride	Potassium Chloride	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Telmisartan	Telmisartan	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Nebivolol Hcl	Nebivolol Hcl	16	suppressed
Ondansetron Odt	Ondansetron	16	11
Primidone	Primidone	16	suppressed
Estradiol	Estradiol	15	suppressed
Fluticasone Propionate	Fluticasone Propionate	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Amiodarone Hcl	Amiodarone Hcl	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Azithromycin	Azithromycin	12	12
Cefdinir	Cefdinir	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	11	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Naproxen	Naproxen	11	suppressed
Rivastigmine	Rivastigmine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error